Edition:
United States

Cosmo Pharmaceuticals NV (COPN.S)

COPN.S on Swiss Exchange

161.40CHF
11:30am EDT
Change (% chg)

CHF0.50 (+0.31%)
Prev Close
CHF160.90
Open
CHF161.00
Day's High
CHF162.40
Day's Low
CHF160.00
Volume
31,745
Avg. Vol
49,902
52-wk High
CHF188.10
52-wk Low
CHF139.90

COPN.S

Chart for COPN.S

About

COSMO Pharmaceuticals SA is a Luxembourg-based pharmaceutical company engaged in the development and production of drugs against selected gastrointestinal diseases. Its clinical research aims to treat Inflammatory Bowel Diseases (IBD), such as ulcerative colitis and Crohn’s disease, as well as colon infections and skin... (more)
No analyst recommendations are available for COPN.S.

Overall

Beta: --
Market Cap(Mil.): €2,239.34
Shares Outstanding(Mil.): 15.04
Dividend: --
Yield (%): --

Financials

  COPN.S Industry Sector
P/E (TTM): -- 29.18 30.12
EPS (TTM): 0.24 -- --
ROI: 5.61 13.76 13.28
ROE: 6.12 14.71 14.44

BRIEF-Cosmo Pharmaceuticals: placing shares were placed at CHF 162.00/shr

* Joh. Berenberg, gossler & co. Kg ("Berenberg") has placed approximately 1.33 million ordinary shares

Mar 31 2017

BRIEF-Cosmo Pharmaceuticals: secondary sale of shares

* Announced on Thursday proposed secondary sale of shares in Cosmo Pharmaceuticals

Mar 31 2017

BRIEF-Cosmo Pharmaceuticals FY operating revenues up 11.6 pct at 67.7 million euros

* FY operating revenues increased by 11.6 pct to 67.7 million euros ($72.89 million)

Mar 24 2017

BRIEF-Cosmo announces details of successful phase III clinical trials of LuMeBlue

* Announces details of successful phase III clinical trials of LuMeBlue which will be presented at its research and development day

Nov 29 2016

Cosmo shares jump on colonoscopy trial results

ZURICH Shares in Swiss-listed drugmaker Cosmo Pharmaceuticals jumped more than 10 percent on Thursday after it reported its dye tablets helped doctors detect intestinal growths during colonoscopies.

Nov 10 2016

CORRECTED-Cosmo shares jump on colonoscopy trial results

ZURICH, Nov 10 Shares in Swiss-listed drugmaker Cosmo Pharmaceuticals jumped more than 10 percent on Thursday after it reported its dye tablets helped doctors detect intestinal growths during colonoscopies.

Nov 10 2016

BRIEF-Cosmo Pharmaceuticals: successful outcome of phase III clinical trial for LuMeBlue

* Announces successful outcome of phase III clinical trial for LuMeBlue

Nov 10 2016

More From Around the Web

Earnings vs. Estimates

No consensus analysis data available.